MacroGenics (MGNX) AI Stock Analysis

• Market Cap: $84.13M
• Dividend Yield: N/A
• Average Volume (3M): 1.14M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.25
• Revenue Growth: -9.70%
• EPS Growth: 23.23%
• Country: US
• Employees: 341
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.27
• Shares Outstanding: 63,258,533
• 10 Day Avg. Volume: 1,542,612
• 30 Day Avg. Volume: 1,139,564
• PEG Ratio: >-0.01
• Price to Book (P/B): 1.75
• Price to Sales (P/S): 1.37
• P/FCF Ratio: -2.82
• Enterprise Value/Market Cap: 0.80
• Enterprise Value/Revenue: 0.53
• Enterprise Value/Gross Profit: 0.72
• Enterprise Value/Ebitda: -1.06
• 1Y Price Target: $3.00
• Price Target Upside: 114.29% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 5
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 41 Neutral
• Price Target: $1.50 ▲(7.14% Upside)

MacroGenics faces significant challenges with profitability and cash flow management, reflected in its financial performance score. Technical analysis indicates bearish momentum, and valuation metrics are weak due to ongoing losses. The recent departure of a key executive adds uncertainty to its strategic direction.

Positive Factors

Strategic Partnerships

The extension of partnerships with companies like Gilead enhances MacroGenics' revenue streams and supports long-term financial stability.

Cash Runway

A strong cash runway until late 2027 provides MacroGenics with the financial flexibility to invest in R&D and strategic initiatives without immediate funding pressures.

Product Development

Continued advancement in ADC programs and clinical trials positions MacroGenics to potentially capture significant market opportunities in oncology.

Negative Factors

Executive Departure

The departure of a key executive may disrupt clinical development and strategic direction, impacting long-term operational stability.

Profitability Challenges

Ongoing profitability issues, as indicated by negative net margins, could limit MacroGenics' ability to reinvest in growth and innovation.

Revenue Decline

A significant year-over-year revenue decline suggests potential challenges in market demand or competitive pressures, impacting future growth prospects.

MacroGenics Business Overview & Revenue Model

Company Description

MacroGenics, Inc. is a biotechnology company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases. The company specializes in leveraging its proprietary technologies, such as the DART® platform, to create bispecific antibodies that can engage multiple targets simultaneously, enhancing therapeutic efficacy and safety. MacroGenics operates primarily in the oncology sector, with a portfolio of product candidates aimed at addressing unmet medical needs in various malignancies.

How the Company Makes Money

MacroGenics generates revenue through a combination of product sales, licensing agreements, and collaborations with pharmaceutical companies. The company earns revenue from the sale of its approved therapeutics, as well as milestone payments and royalties from partnerships that involve the co-development and commercialization of its drug candidates. Significant collaborations with larger biopharmaceutical companies also contribute to its earnings, as these partnerships often include upfront payments and potential future royalties based on sales of the jointly developed products. Additionally, MacroGenics may engage in research agreements that provide funding for the development of specific therapeutic candidates, further diversifying its revenue streams.

MacroGenics Financial Statement Overview

Summary

MacroGenics is navigating a challenging financial landscape with strengths in revenue growth and gross profit margins, but it faces significant hurdles in achieving profitability and managing cash flows. The balance sheet indicates moderate leverage, but the negative return on equity and ongoing losses suggest the need for strategic improvements to enhance financial stability and performance.

Income Statement

MacroGenics shows a mixed performance in its income statement. The company has a high gross profit margin of 89.78% TTM, indicating efficient production, but it struggles with profitability as reflected by a negative net profit margin of -36.62% TTM. Revenue growth is positive at 7.51% TTM, suggesting some growth potential, but the negative EBIT and EBITDA margins indicate ongoing operational challenges.

Balance Sheet

The balance sheet reveals moderate leverage with a debt-to-equity ratio of 0.47 TTM, which is manageable but has increased from previous years. The return on equity is negative at -59.84% TTM, highlighting profitability issues. The equity ratio is not explicitly provided, but the overall financial health suggests a need for improved equity management.

Cash Flow

Cash flow analysis shows a slight improvement in free cash flow growth at 3.01% TTM, but the company still faces challenges with negative operating cash flow. The free cash flow to net income ratio is positive at 1.04 TTM, indicating that the company is generating cash relative to its net losses, which is a positive sign amidst cash flow difficulties.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	126.00M	148.34M	57.19M	150.02M	75.64M	97.76M
Gross Profit	92.83M	136.04M	48.97M	142.63M	72.99M	97.76M
EBITDA	-63.11M	-57.37M	2.02M	-107.89M	-190.86M	-119.10M
Net Income	-75.89M	-66.97M	-9.06M	-119.76M	-202.12M	-129.74M
Balance Sheet
Total Assets	270.76M	261.65M	298.42M	289.51M	335.25M	378.74M
Cash, Cash Equivalents and Short-Term Investments	146.40M	201.67M	229.81M	154.35M	243.62M	272.53M
Total Debt	37.01M	37.46M	33.97M	34.83M	25.47M	29.25M
Total Liabilities	203.76M	145.60M	145.81M	147.50M	95.63M	82.86M
Stockholders Equity	67.00M	116.06M	152.61M	142.01M	239.62M	295.88M
Cash Flow
Free Cash Flow	-164.76M	-72.08M	-79.97M	-90.58M	-150.03M	-117.80M
Operating Cash Flow	-162.47M	-68.37M	-78.20M	-86.96M	-143.83M	-111.90M
Investing Cash Flow	-6.64M	149.30M	-80.08M	70.72M	-36.61M	-7.79M
Financing Cash Flow	69.61M	960.00K	150.36M	1.66M	122.78M	174.34M

MacroGenics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.40
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MGNX, the sentiment is Negative. The current price of 1.4 is below the 20-day moving average (MA) of 1.44, below the 50-day MA of 1.58, and below the 200-day MA of 1.61, indicating a bearish trend. The MACD of -0.05 indicates Negative momentum. The RSI at 44.37 is Neutral, neither overbought nor oversold. The STOCH value of 23.19 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MGNX.

MacroGenics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SEER	54 Neutral	$122.17M	-1.58	-25.74%	―	13.77%	-4.76%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ANIX	49 Neutral	$171.83M	―	-57.94%	―	―	11.78%
ORMP	47 Neutral	$113.44M	2.84	24.38%	―	―	814.20%
SRZN	43 Neutral	$107.90M	-0.90	―	―	-63.96%	-28.50%
MGNX	41 Neutral	$84.13M	―	-81.13%	―	-9.70%	23.23%
ATOS	36 Underperform	$109.55M	-3.77	-48.89%	―	―	-9.42%

MacroGenics Corporate Events

MacroGenics Announces Departure of Chief Medical Officer

On November 14, 2025, MacroGenics announced the departure of Dr. Stephen Eck, its Senior Vice President, Clinical Development and Chief Medical Officer, effective December 31, 2025. Dr. Eck, who joined the company in July 2020, led its clinical development efforts across multiple studies. In his absence, Frank Perabo will assume interim oversight of clinical development, while the company searches for a new Chief Medical Officer. This leadership change may impact MacroGenics’ clinical development operations and strategic direction.